RecruitingPhase 2Phase 3ACTRN12608000236392
Placebo controlled,randomised,crossover study of the efficacy of bosentan in the management of patients with Coronary Slow Flow Phenemenon
Study of bosentan in the management of angina in patients with Coronary Slow Flow phenomenon
Sponsor
Cenral Northern Adelaide Health Service - The Queen Elizabeth Hospital
Enrollment
26 participants
Start Date
May 28, 2007
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- Coronary Slow Flow Phenomenon. Angina frquency>3 episodes/week
Exclusion Criteria1
- Pulmonary hypertension,liver disease.Cyclosporin,glibenclamide,ketoconazole
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Bosentan 125mgs orally twice daily for 4 weeks with 1 week washout prior to crossover
Bosentan 125mgs orally twice daily for 4 weeks with 1 week washout prior to crossover
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000236392